GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cabaletta Bio Inc.
Cabaletta Bio is a biotech company specializing in cell therapy for autoimmune diseases. Its stock price represents a venture bet on a breakthrough in this cutting-edge field. The chart reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Pharma immune
Cabaletta Bio is a clinical-stage biopharmaceutical company developing T-cell-based cell therapies for the treatment of autoimmune diseases. We have classified it in the Pharma: Immunology category. The chart below shows how investors view the application of oncology technologies in emerging areas.
Broad Market Index - GURU.Markets
Cabaletta Bio is a clinical-stage biopharmaceutical company developing T-cell-based cell therapies for autoimmune diseases. As a component of the GURU.Markets index, it applies oncology technologies to emerging areas. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CABA - Daily change in the company's share price Cabaletta Bio Inc.
Shares of Cabaletta, a cell therapy company, exhibit extreme volatility, as measured by change_co. This indicator reflects sensitivity to clinical trial results. This metric is a key component of formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Cabaletta Bio, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with CABA, which focuses on cell therapy, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. Its shares are a bet on a breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovation market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cabaletta Bio Inc.
Cabaletta Bio, Inc.'s year-over-year performance is a story of cell therapy development for autoimmune diseases. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its CAR-T-based approach could fundamentally change the treatment paradigm for these complex diseases.
Annual dynamics of market capitalization of the market segment - Pharma immune
Cabaletta Bio, Inc. is a clinical-stage biotech company developing cell therapies for the treatment of autoimmune diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this cutting-edge field of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cabaletta Bio is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cabaletta Bio Inc.
Cabaletta Bio shares are a bet on cutting-edge gene therapy. Monthly price fluctuations are not tied to current earnings, but rather a direct response to news from the lab: the results of preclinical and clinical trials of their autoimmune disease treatments. The chart shows investor expectations regarding the company's scientific and regulatory success.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. This is one of the most advanced and complex areas in medicine. The dynamics of the biotech sector reflect the shared hopes for breakthroughs. Cabaletta's story is a risky bet that its technology can "reboot" the immune system and cure serious illnesses.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cabaletta Bio, Inc. is a clinical-stage biopharmaceutical company developing CAR-T cell therapy for the treatment of autoimmune diseases. The company's future depends solely on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its cutting-edge approach to "rebooting" the immune system impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotech company developing cell therapies for autoimmune diseases. Its weekly stock price is highly volatile and depends entirely on news about clinical trials of its innovative approach.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. This is one of the most advanced areas of medicine. The chart clearly shows how its stock performance is disconnected from general healthcare trends and is entirely dependent on news about clinical trials.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cabaletta is a biotech company whose shares are driven by news of clinical trials. It's a classic example of an asset that doesn't correlate with the market. The chart clearly demonstrates how much its performance is driven by scientific news.
Market capitalization of the company, segment and market as a whole
CABA - Market capitalization of the company Cabaletta Bio Inc.
Cabaletta Bio's market capitalization reflects investor faith in its cutting-edge cell therapy platform for treating autoimmune diseases. As a clinical-stage company, its price is highly volatile and driven by research progress. It's a high-risk bet that its technology can "reboot" the immune system.
CABA - Share of the company's market capitalization Cabaletta Bio Inc. within the market segment - Pharma immune
Cabaletta Bio is a clinical-stage biotech developing cell-based therapies (CAAR-T) for the treatment of autoimmune diseases. Its market share reflects the potential of its cutting-edge science. The graph is a venture bet that its targeted approach will allow for the treatment of these diseases without suppressing the immune system.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall value of the biotech sector. Cabaletta Bio is a company at the forefront of cell therapy for autoimmune diseases. Its approach is based on CAR-T technology, which "reprograms" immune cells. The potential of this market is enormous, and Cabaletta aims to be a leader in this medical revolution.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. Its market cap reflects the bet that approaches effective in oncology can be applied here as well. The chart below shows the weightings of companies expanding the use of cell therapy.
Book value capitalization of the company, segment and market as a whole
CABA - Book value capitalization of the company Cabaletta Bio Inc.
Cabaletta Bio's foundation is its scientific platform for developing and manufacturing cell therapies (CAAR-T) for the treatment of autoimmune diseases. The book value represents the capital it uses to conduct clinical trials. The graph tells the story of a company investing in a cutting-edge and complex approach to medicine, building its intangible asset.
CABA - Share of the company's book capitalization Cabaletta Bio Inc. within the market segment - Pharma immune
Cabaletta Bio is developing cell therapies for autoimmune diseases. The chart shows its share of actual R&D assets. These are its laboratories, where a platform for developing "smart" cells capable of precisely targeting the cause of the disease is being created.
Market segment balance sheet capitalization - Pharma immune
Cabaletta Bio is a biotech company whose value is locked into its scientific platform. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which highlights its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Cabaletta Bio develops cell therapy targeting B cells for the treatment of autoimmune diseases. The company's assets comprise its scientific platform. A small stake in BCap_All provides the foundation for a highly precise approach that can "reboot" the immune system and lead to remission.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cabaletta Bio Inc.
Cabaletta Bio is a cell therapy company. Its entire market capitalization is a premium to its cash flow. This premium is a bet that its cutting-edge CAR-T technology for treating autoimmune diseases will prove successful.
Market to book capitalization ratio in a market segment - Pharma immune
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. Its value is based almost entirely on its scientific potential. The chart shows the huge premium to book value that investors are paying for the hope of developing breakthrough drugs.
Market to book capitalization ratio for the market as a whole
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. Its entire value lies in its cutting-edge scientific platform. This chart shows the extreme premium investors are willing to pay for this potentially revolutionary technology, ignoring traditional tangible assets.
Debts of the company, segment and market as a whole
CABA - Company debts Cabaletta Bio Inc.
Cabaletta Bio, a biotech company developing cell therapies for autoimmune diseases, funds its cutting-edge research with borrowed capital. Its debt burden directly reflects the high costs of developing and conducting clinical trials for its innovative therapies based on CAR-T technology.
Market segment debts - Pharma immune
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases, one of the most advanced and expensive areas of medicine. This chart shows whether the company is pursuing the standard biotech equity financing model to advance its complex and potentially breakthrough therapies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cabaletta Bio Inc.
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases, one of the most advanced and expensive areas of medicine. This chart shows the company's reliance on debt to finance its unique R&D programs, which is the main financial risk for its investors.
Market segment debt to market segment book capitalization - Pharma immune
Cabaletta Bio is developing CAR-T-based cell therapy for autoimmune diseases. This chart shows debt trends in the biotech sector. For a company operating at the forefront of science, this allows them to assess how they finance their complex and expensive clinical programs and how their financial model compares to other immunology innovators.
Debt to book value of all companies in the market
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. Its operations are at the cutting edge of science and are financed exclusively by equity. This chart, showing the use of debt in the economy, clearly illustrates that Cabaletta's financial model is focused on scientific breakthroughs rather than on stable cash flow to service debt.
P/E of the company, segment and market as a whole
P/E - Cabaletta Bio Inc.
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. This chart reflects investor expectations for its cutting-edge scientific platform. The valuation is not based on current revenues, but rather represents a bet that its treatments will be groundbreaking.
P/E of the market segment - Pharma immune
This chart shows the average valuation for biotech companies, providing context for Cabaletta Bio. It reflects generally high valuations based on hopes for a breakthrough. Comparisons with this chart help understand whether Cabaletta's cutting-edge cell therapy technology for autoimmune diseases is considered more promising than its competitors.
P/E of the market as a whole
Cabaletta Bio is developing CAR-T cell therapy aimed at treating autoimmune diseases. This is one of the most advanced and promising areas in medicine. This chart of overall investor risk appetite in biotech shows whether they are willing to pay a hefty premium for companies that have the potential to cure chronic diseases but are still in the early stages of research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotech developing CAR-T cell therapy for autoimmune diseases. This chart shows the speculative expectations for its cutting-edge approach. The valuation depends entirely on clinical trial results and investor confidence in the potential of this technology to transform treatment paradigms.
%20P%2FE%20Cabaletta%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cabaletta-Bio-Inc.&v=1772557638992 "Chart of the company's future (projected) P/E Cabaletta Bio Inc.")
Future (projected) P/E of the market segment - Pharma immune
Cabaletta Bio is a biotech company focused on developing cell therapies for autoimmune diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It provides insight into the market's confidence in its scientific platform and potential for developing treatments targeting the underlying disease.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772557638996 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Cabaletta Bio is a clinical-stage biotech developing cell therapies for autoimmune diseases. For a company operating at the cutting edge of science, this market risk appetite curve is vital. Funding for their cutting-edge CAR-T therapy research is directly dependent on investor willingness to invest in long-term, capital-intensive projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772557639020 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cabaletta Bio Inc.
Cabaletta Bio is a biotech company developing T-cell-based cell therapies specifically designed to treat autoimmune diseases. This chart shows the financial status of the company, which is at the forefront of cell engineering to combat B-cell diseases.
Profit of companies in the market segment - Pharma immune
Cabaletta Bio develops cell therapies for autoimmune diseases. This chart shows the profitability of the immunology sector. For CABA, this reflects scientific advances in using T cells to combat diseases where the body's own immune system attacks. Their technology aims for precise and targeted treatment.
Overall market profit
Cabaletta Bio is a clinical-stage biotech company developing cell therapy for B-cell autoimmune diseases. This is a cutting-edge approach aimed at curing rather than suppressing symptoms. The company's success depends on clinical data. This total market revenue graph does not reflect the potential of this technology.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cabaletta Bio Inc.
Cabaletta Bio is a biotechnology company developing T-cell-based cell therapies for the treatment of autoimmune diseases. The revenue forecast presented here is speculative and reflects expectations for the success of its cutting-edge scientific platform. Early clinical data is the only significant driver of expectations.
%20profit%20of%20the%20company%20Cabaletta%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cabaletta-Bio-Inc.&v=1772557639180 "Graph of future (projected) profit of the company Cabaletta Bio Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Cabaletta Bio is developing T-cell-based cell therapy targeting autoimmune diseases. The revenue forecast for this cutting-edge segment depends on the success of clinical trials. This chart reflects analysts' belief that technologies proven effective in oncology will revolutionize the treatment of autoimmune diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772557639213 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Cabaletta Bio is a clinical-stage biotech company developing cell therapies for autoimmune diseases. Its future depends on the success of its research. The market profit forecasts shown here reflect investors' overall risk appetite and their willingness to fund long-term scientific development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772557639230 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cabaletta Bio Inc.
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. This chart shows a high speculative valuation. The company is applying CAR-T technology, successful in oncology, to a new class of diseases, and investors are betting on its potential to revolutionize treatment.
P/S market segment - Pharma immune
Cabaletta Bio is a biotech company developing T-cell-based cell therapies specifically designed to treat B-cell autoimmune diseases. This is a cutting-edge approach in immunology. This chart reflects the average revenue estimate for the sector, which helps us understand the high expectations investors have for Cabaletta Bio's scientific platform.
P/S of the market as a whole
Cabaletta Bio is a biotech company developing CAR-T cell therapy for the treatment of B-cell-mediated autoimmune diseases. The company is in clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cabaletta Bio Inc.
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases that target the cause rather than the symptoms. This chart shows how the market values the company based on its future revenue potential. It reflects the company's hopes for targeted and long-term treatments.
%20P%2FS%20Cabaletta%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cabaletta-Bio-Inc.&v=1772557639314 "The graph of the company's future (projected) P/S Cabaletta Bio Inc.")
Future (projected) P/S of the market segment - Pharma immune
Cabaletta Bio is a biotech company developing CAR-T cell therapies specifically designed to treat autoimmune diseases. This chart reflects investors' confidence in its cutting-edge scientific approach and the potential of its platform to offer radically new treatments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772557639321 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Cabaletta Bio is a clinical-stage biotech company developing cell therapies for autoimmune diseases. Their future depends on the success of their trials. This market optimism is vital for CABA. Access to capital for developing breakthrough, but expensive, treatments is only possible if investors have faith in the future and scientific progress.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772557639332 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotechnology company developing cutting-edge cell therapies for the treatment of autoimmune diseases. Currently, the company has no commercial products. This timeline will show whether its scientific platform can lead to approved and marketable drugs.
Sales of companies in the market segment - Pharma immune
Cabaletta Bio is a biotechnology company developing cutting-edge cell therapies for the treatment of autoimmune diseases. Their unique approach aims to precisely target disease-causing cells without suppressing the entire immune system. Currently in clinical development, the company has no commercial revenue.
Overall market sales
Cabaletta Bio is a biotech company developing cell therapies based on CAR-T technology for the treatment of autoimmune diseases. Its goal is to create "living drugs" capable of inducing long-term remission in patients. This total revenue chart includes the healthcare sector, where CABA operates at the forefront of science, aiming to revolutionize the treatment of autoimmune diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cabaletta Bio Inc.
Cabaletta Bio is a biotech company developing CAR-T cell therapy specifically designed to treat autoimmune diseases. This chart reflects analysts' belief in the potential of this cutting-edge technology to create treatments that target the cause, rather than the symptoms, of these diseases.
%20sales%20of%20the%20company%20Cabaletta%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cabaletta-Bio-Inc.&v=1772557639474 "Schedule of future (projected) sales of the company Cabaletta Bio Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Cabaletta Bio is a biotech company developing CAR-T cell therapy for autoimmune diseases. This chart shows forecasts for the advanced cell therapy market, illustrating the enormous potential for technologies originally developed to fight cancer to be applied to a wide range of other diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772557639496 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Cabaletta Bio, which develops cell therapies for autoimmune diseases, sees this chart as a reflection of investment interest in breakthrough medical technologies. The stable economic growth projected here provides the capital needed to conduct complex and expensive clinical trials, which is critical to Cabaletta's success.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772557639521 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cabaletta Bio Inc.
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. Being in the clinical stage, it incurs high R&D expenses. This chart illustrates its current financial model: significant investments in science to create breakthrough treatments that could generate profits in the future.
Market segment marginality - Pharma immune
Cabaletta Bio is a clinical-stage biotech company developing cell therapies for patients with autoimmune diseases. This graph reflects the potential of its scientific platform. High future operating revenue will confirm that its approach can offer long-term remission or cure.
Market marginality as a whole
Cabaletta Bio is a clinical-stage biotech company developing cell therapies for autoimmune diseases. Its value and future depend solely on scientific data and trial results. This total market return chart has no bearing on the world of advanced medicine.
Employees in the company, segment and market as a whole
Number of employees in the company Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotechnology company developing CAR-T cell therapy specifically designed to treat B-cell autoimmune diseases. This graphic shows the team of scientists working to develop a precision therapy capable of "rebooting" the immune system and achieving long-term remission.
Share of the company's employees Cabaletta Bio Inc. within the market segment - Pharma immune
Cabaletta Bio is a biotech company developing T-cell-based cell therapy for the treatment of autoimmune diseases. This highly complex and cutting-edge technology requires top scientists in the fields of immunology and genetic engineering. This graph illustrates the concentration of elite scientific talent required to create a new class of drugs.
Number of employees in the market segment - Pharma immune
Cabaletta Bio is a biotech company developing CAR-T cell therapy for autoimmune diseases. It uses technology proven effective in oncology to combat diseases in which the immune system attacks the body. This graphic shows the elite team of scientists at the forefront of this medical revolution.
Number of employees in the market as a whole
Cabaletta Bio, Inc. is a biotech company developing cell therapies for autoimmune diseases. Their success depends on scientific breakthroughs and access to capital. The overall economic environment, reflected in the employment graph, influences investor willingness to finance long-term, risky projects, which is critical for companies at the forefront of science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cabaletta Bio Inc. (CABA)
Cabaletta Bio, Inc. is a biotech company developing cell therapies for autoimmune diseases. This chart represents their hope. Their astronomical market capitalization per employee is typical for companies at the cutting edge of science. The market prices their technology for the potential to completely cure serious diseases, which is worth billions of dollars.
%20of%20the%20company%20Cabaletta%20Bio%20Inc.%20(CABA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cabaletta-Bio-Inc.-CABA&v=1772557639721 "Chart of market capitalization per employee (in thousands of dollars) of the company Cabaletta Bio Inc. (CABA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. Its valuation is based on the potential of its scientific platform. This chart shows the market valuation of its cutting-edge R&D per employee, an important indicator for the biotech sector.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772557639735 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Cabaletta Bio is a biotech company developing cell therapies for the treatment of B-cell-mediated autoimmune diseases. In this cutting-edge field, this metric reflects scientific potential and shows how investors view its platform, which could offer a targeted and potentially curative treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772557639747 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cabaletta Bio Inc. (CABA)
Cabaletta Bio is a clinical-stage biotech company developing cell therapy (CAR-T-based) for the treatment of autoimmune diseases. This graph is negative. The company consists of scientists engaged in R&D. There is no profit; all funds are spent on development and clinical trials, which, if successful, will generate future revenue.
%20Chart%20Cabaletta%20Bio%20Inc.%20(CABA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cabaletta-Bio-Inc.-CABA&v=1772557639752 "Company Profit Per Employee (in thousands of dollars) Chart Cabaletta Bio Inc. (CABA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Cabaletta Bio is a biotech company developing cell therapy (CAR-T) for autoimmune diseases by reprogramming patients' B cells. This chart represents an industry benchmark. For R&D biotech companies operating at the cutting edge of science, it serves as a benchmark, demonstrating the potential profitability the sector aspires to achieve if their complex therapeutic platform is successful.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772557639762 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Cabaletta Bio is a clinical-stage biotech company focused on developing cell therapies (CAR-T) specifically for the treatment of autoimmune diseases. This is R&D. The chart shows the R&D investment (negative return) per scientist working on this complex platform for "retraining" the immune system.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772557639770 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cabaletta Bio Inc. (CABA)
Cabaletta Bio is a biotech company developing cell therapies for autoimmune diseases. This graph reflects the intensive clinical trial phase. If its therapy proves successful, the dramatic increase in revenue per employee will demonstrate the enormous value of its innovative approach to treating these complex diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cabaletta-Bio-Inc.-CABA&v=1772557639785 "Sales chart per company employee Cabaletta Bio Inc. (CABA)")
Sales per employee in the market segment - Pharma immune
Cabaletta Bio (CABA) is a clinical-stage biotech developing cell therapy (CAR-T) for the treatment of autoimmune diseases. They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average.
Sales per employee for the market as a whole
Cabaletta Bio is a biotech company developing cell therapy (CAR-T) for the treatment of complex autoimmune diseases. This is cutting-edge science. This graph will likely show zero revenue, as their team of scientists is in clinical trials and does not yet have a commercial product.
Short shares by company, segment and market as a whole
Shares shorted by company Cabaletta Bio Inc. (CABA)
Cabaletta Bio (CABA) is a clinical-stage biotech developing CAR-T-based cell therapies for autoimmune diseases. This chart shows bearish bets. Like Kyverna (KYTX), the high short interest reflects investor skepticism about the safety and economic feasibility of using complex CAR-T therapies outside of oncology.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cabaletta-Bio-Inc.-CABA&v=1772557639854 "Short Shares Chart for the Company Cabaletta Bio Inc. (CABA)")
Shares shorted by market segment - Pharma immune
Cabaletta Bio (CABA) is a biotech company developing CAR-T cell therapy for the treatment of B-cell-mediated autoimmune diseases. This chart illustrates the general skepticism in the cell therapy sector, reflecting investor concerns about the safety and efficacy of CAR-T cell therapy outside of oncology.
Shares shorted by the overall market
Cabaletta Bio is a clinical-stage biotech company working in cell therapy. Its value reflects its hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they require constant refinancing for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cabaletta Bio Inc. (CABA)
Cabaletta Bio is a biotech company working in the cutting-edge field of CAR-T therapy, not for cancer, but for autoimmune diseases. This is a highly speculative R&D bet. This chart measures the level of hype. It shows when data euphoria (overbought) or doubts about the platform (oversold) peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cabaletta-Bio-Inc.-CABA&v=1772557639934 "RSI 14 indicator chart for the company's stock Cabaletta Bio Inc. (CABA)")
RSI 14 Market Segment - Pharma immune
Cabaletta Bio is a clinical-stage biotech developing advanced cell therapies (CARTA-based) for the treatment of B-cell autoimmune diseases. This chart reflects overall sentiment in the biotech sector and helps assess how the market views this speculative cell therapy industry.
RSI 14 for the overall market
Cabaletta Bio (CABA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CABA (Cabaletta Bio Inc.)
Cabaletta Bio is a biotech company developing cell therapies (T-cell-based, including CAR-T) for the treatment of B-cell-mediated autoimmune diseases. This chart shows the speculative average price target from analysts based on their valuation of this advanced R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CABA-Cabaletta-Bio-Inc.&v=1772557640057 "A chart showing analyst consensus forecasts for the expected stock price. CABA (Cabaletta Bio Inc.)")
The difference between the consensus estimate and the actual stock price CABA (Cabaletta Bio Inc.)
Cabaletta Bio is a clinical-stage biotech company working in the hot field of CAR-T cell therapy. They are targeting autoimmune diseases (lupus, myasthenia gravis). This chart reflects analysts' high expectations for their R&D platform and the chances of a breakthrough in this emerging, competitive field of medicine.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CABA-Cabaletta-Bio-Inc.&v=1772557640079 "A chart showing the difference between the consensus forecast and the actual stock price. CABA (Cabaletta Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Cabaletta Bio (CABA) is a biotech company developing cellular therapies (CAR-T) for the treatment of complex autoimmune diseases. This chart shows analysts' overall expectations for the immunopharmaceutical sector. It reflects whether experts believe this technology will have a breakthrough beyond oncology.
Analysts' consensus forecast for the overall market share price
Cabaletta Bio is a biotech company specializing in developing CAR-T cell therapies for autoimmune diseases. This chart shows the overall risk appetite. For Cabaletta, working in one of the most advanced and expensive areas of medicine, overall market optimism is critical to attracting the capital needed to fund research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cabaletta Bio Inc.
Cabaletta Bio is a biotech company taking CAR-T technology (used to treat cancer) and applying it to rebooting the immune system in autoimmune diseases (lupus, myasthenia gravis). This chart is a clear indicator of faith in their science. It reflects the market's assessment of their clinical data and their chances in this hot new field.
AKIMA Market Segment Index - Pharma immune
Cabaletta Bio is a biotech company developing cell therapy (CAR-T) specifically for the treatment of B-cell autoimmune diseases. This chart shows the average index for the immunology sector. It helps investors assess how Cabaletta's highly specialized scientific approach compares to the industry average.
The AKIM Index for the overall market
Cabaletta Bio is a biotech company developing cell therapy (CAART) for the treatment of autoimmune diseases. It aims to "cure" the underlying cause. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to funding this cutting-edge scientific platform.
